Lysine-specific demethylase 1 controls key OSCC preneoplasia inducer STAT3 through CDK7 phosphorylation during oncogenic progression and immunosuppression

Abstract

Oral squamous cell carcinoma (OSCC) progresses from preneoplastic precursors via genetic and epigenetic alterations. Previous studies have focused on the treatment of terminally developed OSCC. However, the role of epigenetic regulators as therapeutic targets during the transition from preneoplastic precursors to OSCC has not been well studied. Our study identified lysine-specific demethylase 1 (LSD1) as a crucial promoter of OSCC, demonstrating that its knockout or pharmacological inhibition in mice reversed OSCC preneoplasia. LSD1 inhibition by SP2509 disrupted cell cycle, reduced immunosuppression, and enhanced CD4+ and CD8+ T-cell infiltration. In a feline model of spontaneous OSCC, a clinical LSD1 inhibitor (Seclidemstat or SP2577) was found to be safe and effectively inhibit the STAT3 network. Mechanistic studies revealed that LSD1 drives OSCC progression through STAT3 signaling, which is regulated by phosphorylation of the cell cycle mediator CDK7 and immunosuppressive CTLA4. Notably, LSD1 inhibition reduced the phosphorylation of CDK7 at Tyr170 and eIF4B at Ser422, offering insights into a novel mechanism by which LSD1 regulates the preneoplastic-to-OSCC transition. This study provides a deeper understanding of OSCC progression and highlights LSD1 as a potential therapeutic target for controlling OSCC progression from preneoplastic lesions.

References

[1] TanY, et al. . Oral squamous cell carcinomas: state of the field and emerging directions. Int J. Oral. Sci., 2023, 15: 44.

[2] SiegelRL, MillerKD, JemalA. Cancer statistics, 2019. CA Cancer J. Clin., 2019, 69: 7-34.

[3] JamiesonCHM, WeissmanIL. Stem-cell aging and pathways to precancer evolution. N. Engl. J. Med., 2023, 389: 1310-1319.

[4] CrosbyD, et al. . Early detection of cancer. Science, 2022, 375. eaay9040

[5] ChenZ, LauKS. Advances in mapping tumor progression from precancer atlases. Cancer Prev. Res., 2023, 16: 439-447.

[6] PennycuickA, et al. . Immune surveillance in clinical regression of preinvasive squamous cell lung cancer. Cancer Discov., 2020, 10: 1489-1499.

[7] KarlssonK, et al. . Deterministic evolution and stringent selection during preneoplasia. Nature, 2023, 618: 383-393.

[8] LinG, et al. . Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncol. Lett., 2015, 10: 901-906.

[9] ChenY, et al. . The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal Transduct. Target Ther., 2020, 5: 143.

[10] SuskiJM, BraunM, StrmiskaV, SicinskiP. Targeting cell-cycle machinery in cancer. Cancer Cell, 2021, 39: 759-778.

[11] SatpathyS, et al. . A proteogenomic portrait of lung squamous cell carcinoma. Cell, 2021, 184: 4348-4371.e4340.

[12] AlsaqerSF, et al. . Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget, 2017, 8: 73372-73386.

[13] BaisMV, KukuruzinskaM, TrackmanPC. Orthotopic non-metastatic and metastatic oral cancer mouse models. Oral. Oncol., 2015, 51: 476-482.

[14] StewartCA, ByersLA. Altering the course of small cell lung cancer: targeting cancer stem cells via LSD1 inhibition. Cancer Cell, 2015, 28: 4-6.

[15] HollebecqueA, et al. . Phase I study of lysine-specific demethylase 1 inhibitor, CC-90011, in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma. Clin. Cancer Res., 2021, 27: 438-446.

[16] AlhousamiT, et al. . Inhibition of LSD1 attenuates oral cancer development and promotes therapeutic efficacy of immune checkpoint blockade and YAP/TAZ inhibition. Mol. Cancer Res., 2022, 20: 712-721.

[17] GoldmanO, et al. . Early infiltration of innate immune cells to the liver depletes HNF4alpha and promotes extrahepatic carcinogenesis. Cancer Discov., 2023, 13: 1616-1635.

[18] Tolomeo M., Cascio A. The multifaced role of STAT3 in cancer and its implication for anticancer therapy. Int. J. Mol. Sci.22, (2021).

[19] WangY, ShenY, WangS, ShenQ, ZhouX. The role of STAT3 in leading the crosstalk between human cancers and the immune system. Cancer Lett., 2018, 415: 117-128.

[20] HuY, DongZ, LiuK. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J. Exp. Clin. Cancer Res., 2024, 43: 23.

[21] ZouS, et al. . Targeting STAT3 in cancer Immunotherapy. Mol. Cancer, 2020, 19. 145

[22] OldriniB, et al. . EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. Nat. Commun., 2017, 8. 2035

[23] ChenDS, MellmanI. Elements of cancer immunity and the cancer-immune set point. Nature, 2017, 541: 321-330.

[24] LeachDR, KrummelMF, AllisonJP. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996, 271: 1734-1736.

[25] WingK, et al. . CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, 322: 271-275.

[26] WangZ, et al. . Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nat. Commun., 2019, 10. 5546

[27] KhammanivongA, et al. . A novel MCT1 and MCT4 dual inhibitor reduces mitochondrial metabolism and inhibits tumour growth of feline oral squamous cell carcinoma. Vet. Comp. Oncol., 2020, 18: 324-341.

[28] CannonCM, et al. . Therapeutic targeting of protein kinase CK2 gene expression in feline oral squamous cell carcinoma: a naturally occurring large-animal model of head and neck cancer. Hum. Gene Ther. Clin. Dev., 2017, 28: 80-86.

[29] RodneyAR, et al. . Genomic landscape and gene expression profiles of feline oral squamous cell carcinoma. Front Vet. Sci., 2023, 10. 1079019

[30] Sanchez-Molina S. et al. Ewing sarcoma meets epigenetics, immunology and nanomedicine: moving forward into novel therapeutic strategies. Cancers14, 5473 (2022).

[31] LiuX, et al. . RNA sequencing analysis of the CAL-27 cell response to over-expressed ZNF750 gene revealed an extensive regulation on cell cycle. Biomed. Pharmacother., 2019, 118. 109377

[32] KhanMM, et al. . Total RNA sequencing reveals gene expression and microbial alterations shared by oral pre-malignant lesions and cancer. Hum. Genomics, 2023, 17. 72

[33] St PaulM, OhashiPS. The roles of CD8(+) T cell subsets in antitumor immunity. Trends Cell Biol., 2020, 30: 695-704.

[34] Alspach E., Lussier D. M., Schreiber R. D. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb. Perspect. Biol.11, a028480 (2019).

[35] TakenakaY, et al. . Transaminase activity predicts survival in patients with head and neck cancer. PLoS One, 2016, 11: e0164057.

[36] Knittelfelder O. et al. The AST/ALT (De Ritis) ratio predicts survival in patients with oral and oropharyngeal cancer. Diagnostics10, 973 (2020).

[37] ZhouJ, HeZ, MaS, LiuR. AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer. Cancer Med., 2020, 9: 5672-5677.

[38] ScheipnerL, et al. . The AST/ALT ratio is an independent prognostic marker for disease-free survival in stage II and III colorectal carcinoma. Anticancer Res., 2021, 41: 429-436.

[39] ZhenH, et al. . SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling. Acta Biochim Biophys. Sin., 2021, 53: 1098-1105.

[40] YangJ, et al. . Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proc. Natl. Acad. Sci. USA, 2010, 107: 21499-21504.

[41] QureshyZ, et al. . STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clin. Cancer Res., 2022, 28: 4737-4746.

[42] JohnsonDE, O’KeefeRA, GrandisJR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol., 2018, 15: 234-248.

[43] ShiY, et al. . Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 2004, 119: 941-953.

[44] SavaGP, FanH, CoombesRC, BuluwelaL, AliS. CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev., 2020, 39: 805-823.

[45] PatelH, et al. . ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol. Cancer Ther., 2018, 17: 1156-1166.

[46] LolliG, LoweED, BrownNR, JohnsonLN. The crystal structure of human CDK7 and its protein recognition properties. Structure, 2004, 12: 2067-2079.

[47] ZhangH, et al. . CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer. Cancer Cell, 2020, 37: 37-54.e39.

[48] RubioA, GarlandGD, SfakianosA, HarveyRF, WillisAE. Aberrant protein synthesis and cancer development: The role of canonical eukaryotic initiation, elongation and termination factors in tumorigenesis. Semin Cancer Biol., 2022, 86: 151-165.

[49] SureshS, et al. . eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat. Cancer, 2020, 1: 533-545.

[50] WuC, et al. . CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis. Oncogene, 2023, 42: 1321-1330.

[51] WittK, et al. . Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer. Cancer Immunol. Immunother., 2021, 70: 3155-3166.

[52] GuinnZ, LampeAT, BrownDM, PetroTM. Significant role for IRF3 in both T cell and APC effector functions during T cell responses. Cell Immunol., 2016, 310: 141-149.

[53] GuinnZ, BrownDM, PetroTM. Activation of IRF3 contributes to IFN-gamma and ISG54 expression during the immune responses to B16F10 tumor growth. Int. Immunopharmacol., 2017, 50: 121-129.

[54] TianM, et al. . IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of beta-catenin. Nat. Commun., 2020, 11. 5762

[55] JiaoS, et al. . Targeting IRF3 as a YAP agonist therapy against gastric cancer. J. Exp. Med., 2018, 215: 699-718.

[56] HarringtonKJ, et al. . Efficacy and safety of nivolumab plus ipilimumab vs nivolumab alone for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck: the phase 2 checkmate 714 randomized clinical trial. JAMA Oncol., 2023, 9: 779-789.

[57] SchoenfeldJD, et al. . Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol., 2020, 6: 1563-1570.

[58] TangXH, et al. . Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide. Proc. Natl. Acad. Sci. USA, 2014, 111: 8907-8912.

[59] KerenyiMA, et al. . Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation. Elife, 2013, 2. e00633

[60] YoshimotoT, et al. . Osteocytes directly regulate osteolysis via MYD88 signaling in bacterial bone infection. Nat. Commun., 2022, 13. 6648

[61] CushingVI, et al. . High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design. Nat. Commun., 2024, 15. 2265

[62] ChinCH, et al. . cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol., 2014, 8. S11

Funding

U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR)(R01 DE031413)

RIGHTS & PERMISSIONS

The Author(s)